Table 1.

Schedule of Enrolment, Intervention and Assessments.

MDMS	STUDY PERIOD—12 Months
	Consent	Allocation	Post-allocation	Close-out
TIMEPOINT	Baseline		6 months	12 months
ENROLMENT:
Eligibility screen	X
Informed consent	X
Allocation		X
INTERVENTION: MDMS
ASSESSMENTS:
HbA1c #	X		X	X
Blood pressure, Body Mass Index, Lipid profile		X	X	X
Patient satisfaction survey and Diabetes Distress Scale		X	X	X
CDE satisfaction survey				X
Health-related Quality-of-Life—Assessment of Quality-of-Life (AQoL-8D) questionnaire		X	X	X
Self-reported hypoglycaemic events survey			X	X
Clinic Attendance Rates
Other Assessments
Patient Acceptability Survey—Intervention group (SUTAQ) ^			X	X
Clinic Appointment types
Cost-estimations for delivery of intervention

MDMS—Mobile Diabetes Management System; ^# HbA1c also measured at three months; CDE—Credentialled Diabetes Educator; ^ SUTAQ—Service User Technology Acceptability Questionnaire.